Laboratory of Epigenetics, Division of Basic Research, Instituto Nacional de Cancerología, Mexico City, Mexico.
Pharmacogenet Genomics. 2011 Dec;21(12):894-901. doi: 10.1097/FPC.0b013e32834bec2b.
N-acetyltransferase 2 (NAT2) catalyzes the bioactivation and/or detoxification of drugs and carcinogens. The aim of this study was to establish the correlation between the NAT2 genotype and the acetylating phenotype in a Mexican population using sulfamethazine as a probe. From a total of 122 individuals, 73 (59.8%) were slow and 49 (40.2%) were fast acetylators. Eleven individuals (9%) had the wild-type genotype (NAT24/NAT24). The most frequent genotype was NAT24/NAT25B observed in 20.66% of individuals. In conclusion, our results show that an accurate prediction of the acetylation phenotype by genotyping can be achieved in around half of the population. Further studies with a larger number of individuals are required to establish correlations between phenotype and genotype in half of that patients having a genotype combined with slow/rapid alleles.
N-乙酰基转移酶 2(NAT2)催化药物和致癌物质的生物活化和/或解毒。本研究的目的是使用磺胺甲恶唑作为探针,建立墨西哥人群中 NAT2 基因型与乙酰化表型之间的相关性。在总共 122 个人中,73 人(59.8%)为慢乙酰化者,49 人(40.2%)为快乙酰化者。11 个人(9%)具有野生型基因型(NAT24/NAT24)。最常见的基因型是 NAT24/NAT25B,在 20.66%的个体中观察到。总之,我们的结果表明,通过基因分型可以在大约一半的人群中准确预测乙酰化表型。需要进一步对更多个体进行研究,以确定表型和基因型之间的相关性,特别是在具有慢/快等位基因组合基因型的患者中。